Key Takeaways
- Health Canada has approved lecanemab (Leqembi) for early Alzheimer’s disease the first disease-modifying Alzheimer’s therapy approved in Canada.
- The CLARITY AD Phase 3 trial showed a 27% slowing of clinical decline vs placebo over 18 months in early AD patients.
- Annual drug cost is approximately $45,000 CAD; coverage decisions from provincial formularies are expected over the next 12–18 months.
- Canadian companies with Alzheimer’s-adjacent programs including Neurimmune Canada and AbCellera may benefit from increased sector interest.
After two years of watching the United States and Japan lead the way, Canada has its own approved disease-modifying Alzheimer’s therapy. Health Canada’s authorization of lecanemab (Leqembi) the anti-amyloid monoclonal antibody developed by Eisai and Biogen marks a turning point not just for the estimated 747,000 Canadians living with dementia, but for the domestic neuroscience investment landscape that has long struggled to attract the capital commanded by oncology and rare disease.
The Science Behind Lecanemab
Lecanemab targets soluble amyloid beta protofibrils a specific form of the misfolded protein that accumulates in the brains of Alzheimer’s patients decades before symptoms appear. Unlike earlier amyloid-targeting antibodies that failed in large Phase 3 trials, lecanemab’s mechanism focuses on a particular conformation of amyloid beta believed to be especially toxic to neurons. The drug is administered intravenously every two weeks and requires confirmation of amyloid pathology through PET imaging or cerebrospinal fluid biomarkers before initiation.
The CLARITY AD Phase 3 trial enrolled 1,795 participants with early symptomatic Alzheimer’s disease either mild cognitive impairment or mild Alzheimer’s dementia with confirmed amyloid pathology. After 18 months, patients on lecanemab experienced a 27% slower rate of clinical decline on the CDR-SB (Clinical Dementia Rating Sum of Boxes) scale compared to placebo. Secondary endpoints including cognitive composite scores and functional assessments showed consistent directional benefit, though absolute effect sizes were modest.
| Endpoint | Lecanemab | Placebo | Difference | p-value |
|---|---|---|---|---|
| CDR-SB change (18 months) | +1.21 points | +1.66 points | -0.45 points | <0.001 |
| ADAS-Cog14 change | +4.14 points | +5.58 points | -1.44 points | <0.001 |
| Amyloid PET centiloid reduction | -55.5 CL | +3.6 CL | -59.1 CL | <0.001 |
| ARIA-E rate | 12.6% | 1.7% | +10.9% | <0.001 |
| Symptomatic ARIA rate | 2.8% | 0.0% | +2.8% | 0.003 |
Access and Coverage: The $45,000 Problem
Health Canada’s approval is the beginning of the access journey, not the end. The drug’s Canadian list price has been announced at approximately $44,800 per patient per year positioning it in line with its US pricing of roughly US$26,500 per year, adjusted for currency. That price point will face scrutiny from the Patented Medicine Prices Review Board (PMPRB), which has expanded its comparator framework in 2026 and may flag lecanemab as a candidate for a price reduction notice.
Provincial formulary decisions are expected to take between 12 and 24 months. The Canadian Drug Agency (CDA-AMC) will conduct a health technology assessment that weighs clinical benefit against cost-effectiveness. Based on the clinical trial data, early HTA analyses in comparable markets have suggested that lecanemab’s cost per quality-adjusted life year (QALY) exceeds commonly accepted thresholds at list price suggesting that negotiated rebates will be essential for broad public coverage.
Canadian Companies in the Alzheimer’s Ecosystem
Lecanemab’s Canadian approval creates a halo effect for domestic companies working in adjacent areas. AbCellera Biologics (ABCL), the Vancouver-based antibody discovery company that has partnered with major pharma on neurology programs, has seen analyst commentary highlight its platform’s relevance to next-generation amyloid and tau programs. Neurimmune Canada, the Canadian subsidiary of the Swiss biotech behind the original lecanemab discovery partnership with Eisai, maintains a presence in Toronto’s Discovery District.
The broader implication for Canadian investors is that Alzheimer’s long considered a regulatory graveyard after a decade of Phase 3 failures is now a commercially viable neuroscience category. That should attract venture capital and public market financing to Canadian-listed companies working on companion diagnostics, caregiving technology, and next-generation disease-modifying candidates.
The Bottom Line
Lecanemab’s Canadian approval is a landmark moment for neuroscience, but the real test is access. At $45,000 per year, with mandatory MRI monitoring adding additional healthcare system costs, the therapy will only reach the patients who need it if provincial formularies negotiate coverage a process that will play out over the next 12 to 24 months. For investors, the approval validates the amyloid hypothesis and opens a disease-modifying Alzheimer’s market that could reach $800 million annually in Canada by 2030 if coverage is broad; the key variable is now the HTA and pricing negotiation process, not the science.